U.S. Markets close in 2 hrs 54 mins
  • S&P 500

    4,048.09
    -28.48 (-0.70%)
     
  • Dow 30

    34,254.90
    -140.11 (-0.41%)
     
  • Nasdaq

    11,374.16
    -108.29 (-0.94%)
     
  • Russell 2000

    1,882.79
    +1.12 (+0.06%)
     
  • Crude Oil

    80.40
    -0.82 (-1.01%)
     
  • Gold

    1,809.30
    -5.90 (-0.33%)
     
  • Silver

    23.26
    +0.42 (+1.83%)
     
  • EUR/USD

    1.0532
    +0.0003 (+0.0316%)
     
  • 10-Yr Bond

    3.5590
    +0.0300 (+0.85%)
     
  • Vix

    19.60
    -0.24 (-1.21%)
     
  • GBP/USD

    1.2281
    +0.0025 (+0.2039%)
     
  • USD/JPY

    134.6130
    -0.6930 (-0.5122%)
     
  • BTC-USD

    16,950.48
    -26.94 (-0.16%)
     
  • CMC Crypto 200

    402.28
    +0.86 (+0.21%)
     
  • FTSE 100

    7,556.23
    -2.26 (-0.03%)
     
  • Nikkei 225

    27,777.90
    -448.18 (-1.59%)
     

Zymeworks Announces Participation in Upcoming Investor Conferences

VANCOUVER, British Columbia & SEATTLE, March 03, 2022--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in upcoming investor conferences during March:

  • Barclays Global Healthcare Conference. Zymeworks will participate in one-on-one meetings and will present on March 16th at 8:00 a.m. ET in Miami, FL.

  • Citi’s 2022 Winter Biotech Virtual Bus Tour. Zymeworks will participate virtually in a fireside chat on March 23rd at 2:45 p.m. ET.

The fireside chat and presentation will be webcast live with dial-in details and webcast replays available on Zymeworks’ website at http://ir.zymeworks.com/events-and-presentations.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. Zymeworks’ second clinical candidate, ZW49, is a novel bispecific HER2‑targeted antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker and cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with global biopharmaceutical companies. For more information on our ongoing clinical trials visit www.zymeworksclinicaltrials.com. For additional information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220303005388/en/

Contacts

Investor Inquiries:
Jack Spinks
(604) 678-1388
ir@zymeworks.com

Media Inquiries:
Diana Papove
(604) 678-1388
media@zymeworks.com